Stifel reiterates Inhibrx Biosciences stock rating on drug potential By Investing.com

Stifel reiterated a Buy rating on Inhibrx Biosciences and maintained a $150 price target, implying meaningful upside from the current $83.11 share price. The call highlighted renewed enthusiasm for INBRX-106, a hexavalent OX40 agonist, with KOLs citing tumor-localized activity and potential to improve outcomes in immunotherapy-refractory and first-line head and neck squamous cell carcinoma settings. The article is supportive for the stock, though the impact is likely incremental rather than immediately market-moving.

Analysis

INBX is becoming a classic sentiment-over-fundamentals biotech tape: the market is rewarding optionality on a potentially differentiated mechanism before the data package is mature enough to underwrite a durable commercial franchise. The second-order winner is the platform story itself — if the next readout shows even modest efficacy in refractory populations, the valuation framework shifts from single-asset speculation to a broader engine for follow-on OX40 or adjacent immunology programs. That matters because the upside is no longer just one indication; it becomes a perceived discovery platform premium.

The key competitive dynamic is that this thesis only works if INBX keeps proving it can do what prior OX40 programs could not: translate biology into a clinically meaningful survival tail, not just an ORR bump. If the interim first-line signal disappoints, the stock can re-rate violently lower because the current price already embeds a lot of optimism and the market will quickly question whether the mechanism is biologically elegant but commercially noisy. In that scenario, the loser is not only INBX holders but also smaller adjacently valued checkpoint/immune agonist names, which can de-rate as investors reassess the whole sub-segment’s probability-weighted terminal value.

The most important catalyst window is the next 1-2 data disclosures, not the next 12 months. Near term, the stock should trade on whether management can sustain a narrative of clean safety plus enough efficacy to keep peak-sales math alive; longer term, the real value comes only if combination use in earlier-line or peri-operative settings becomes credible, which could multiply addressable patients by several times. The contrarian miss in the current debate is that the market may be focusing too much on headline response rates; for immune-oncology, the more important question is whether the drug can improve durability without adding cost or toxicity that makes it unattractive to clinicians and payers.

Key Decisions for Investors

• Fade strength in INBX into event risk: take a tactical short or buy put spreads into the next clinical update, targeting a 3-6 week horizon. Risk/reward is attractive if the stock is already discounting a best-case readout; a miss can compress multiples quickly.
• If forced long, prefer a call spread rather than equity in INBX over the next 1-3 months. That caps downside from an overextended valuation while preserving upside to the next catalyst.
• Pair trade: long a diversified immuno-oncology platform name with later-stage clinical de-risking, short INBX, to isolate mechanism-risk versus platform-quality risk over the next quarter.
• Use a rally above prior highs to reduce exposure; if the next data release is clean, treat it as a liquidity event unless survival-tail evidence emerges. The trade should be sized as a catalyst option, not a core holding.